

Other Information

The Rural Health Research Centers Grant Program has been determined to be a program which is not subject to the provisions of Executive Order 12372 concerning intergovernmental review of Federal programs.

The OMB Catalog of Federal Domestic Assistance number is 93.155.

Dated: February 29, 1996.

Ciro V. Sumaya,
Administrator.

[FR Doc. 96-5113 Filed 3-4-96; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health**National Center for Human Genome Research; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix), notice is hereby given of the following meeting:

Name of Committee: Human Genome Research Initial Review Group.

Date: March 18, 1996.

Time: 2:00-6:00 pm.

Place: Teleconference, NIH, Building 38A, Room 605, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402-0838.

Purpose/Agenda: To review and evaluate grant applications and/or contract proposals. The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: February 28, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-5019 Filed 3-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Nursing Research; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Nursing Science Review Committee.

Date: March 14-15, 1996.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, Chase Meeting Room, 5520 Wisconsin Avenue, Bethesda, Maryland 20815.

Contact Person: Dr. Mary Stephens-Frazier, 9000 Rockville Pike, Building 45, Room 3AN.12, Bethesda, Maryland 20892, (301) 594-5971.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the partial shutdown of the Federal Government and urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Programs No. 93.361, Nursing Research, National Institutes of Health.)

Dated: February 27, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-5018 Filed 3-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Environmental Health Sciences; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Environmental Health Sciences Special Emphasis Panel (SEP) meeting:

Name of SEP: Endocrine Disrupting Chemicals and Women's Health Outcomes (RFA-96-003).

Date: March 19-21, 1996.

Time: 8:00 P.M.

Place: (3/19/96) Omni Europa Hotel, Research Triangle Park, NC. (3/20-21/96) NIEHS, South Campus Building 101-C, Research Triangle Park, NC.

Contact Person: Dr. Carol Shreffler, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-1445.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to this meeting due to the

urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.113, Biological Response to Environmental Agents; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Resource and Manpower Development, National Institutes of Health.)

Dated: February 28, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-5114 Filed 3-4-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Institute of Mental Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications.

Committee Name: National Institute of Mental Health Special Emphasis Panel.

Date: March 21, 1996.

Time: 10 a.m.

Place: Georgetown Holiday Inn, 2101 Wisconsin Avenue, N.W., Washington, DC 20007.

Contact Person: Donna Ricketts, Parklawn, Room 9-101, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301-443-3936.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers 93.242, 93.281, 93.282).

Dated: February 28, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-5115 Filed 3-4-96; 8:45 am]

BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration**Cosponsorship of the Caring for Every Child's Mental Health: Communities Together Campaign**

AGENCY: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice of opportunity for cosponsorship.

SUMMARY: The Center for Mental Health Services (CMHS), a component of the

Substance Abuse and Mental Health Services Administration (SAMHSA), announces the opportunity for for-profit and nonprofit organizations to cosponsor the Caring for Every Child's Mental Health: Communities Together Campaign.

DATES: To receive consideration, requests to participate as a cosponsor must be received by Ms. Charlotte Mehuron, Director, Office of External Liaison, CMHS, Parklawn Building, Room 13-103, 5600 Fishers Lane, Rockville, Maryland 20857; Fax (301) 443-5163. There are no deadlines applicable to this cosponsorship opportunity.

FOR FURTHER INFORMATION CONTACT: Ms. Valna Montgomery, Project Officer, Office of External Liaison, CMHS, Parklawn Building, Room 13-103, 5600 Fishers Lane, Rockville, Maryland 20857; (301) 443-2792.

SUPPLEMENTARY INFORMATION:

Background

America's young people are at risk, and they desperately need the Nation's attention. Preliminary studies suggest that, at any given time, at least one in five children and adolescents may have behavioral, emotional, or mental health problems that, without help, can lead to school failure, alcohol and other drug use, family discord, or violence. At least 1 in 20—or as many as 3 million young people—may have a serious emotional disturbance that disrupts his or her ability to function. Tragically, an estimated two-thirds of all these young people are not getting the help they need.

Recognizing the need for increased national awareness of and support for children and adolescents with mental health problems and their families, the CMHS initiated a 4-year national education campaign in October 1994. The campaign, Caring for Every Child's Mental Health: Communities Together, hereinafter called Children's Campaign, is managed by the CMHS Office of External Liaison in collaboration with the Child, Adolescent and Family Branch, Division of Demonstration Programs, CMHS. CMHS is also collaborating with the National Institute of Mental Health, a component of the National Institutes of Health (NIH) and the Maternal and Child Health Bureau in the Health Resources and Services Administration (HRSA). SAMHSA, HRSA, and NIH are agencies in the U.S. Department of Health and Human Services.

The goals of the Children's Campaign are to: (1) Increase public awareness that the mental health of every child and

adolescent is as important as physical health; (2) help families, educators, health care and social service professionals, and others recognize mental health problems in children and adolescents, and seek appropriate intervention and services early; (3) diminish the stigma associated with mental health problems; (4) assist and support the Comprehensive Community Mental Health Services for Children Program grantees with their community-based education; and (5) nationally disseminate knowledge gained from model programs and science-based research.

Requirements of Cosponsorship

The Children's Campaign is seeking partnership with one or more public and private for-profit and nonprofit organizations to develop and distribute information to effectively impart the Children's Campaign messages to target groups, such as children and adolescents and their families; teachers, counselors, and principals; youth organizations; primary care providers and mental health care professionals; government agencies; community organizations; and the general public. The Campaign messages are:

- Every child's mental health is important.
- Many children have mental health problems.
- These problems are real and painful and can be recognized and treated.
- Caring families and communities working together can help.
- Information is available; call (800) 789-2647.

CMHS will reserve the right to determine the form and content of the information provided to the target groups. We envision cosponsorship with a wide variety of organizations concerned about children and adolescents with mental health problems and their families in the development and dissemination of information. The duties of the cosponsors may include such activities as implementation of an information campaign for dissemination of the Children's Campaign messages, including but not limited to, printing brochures or booklets; production of public service announcements or videos; press briefings and media events; and production and distribution of other materials, such as posters, flyers, paid advertising, and an exhibit designed for young people, families, educators or health care providers.

Availability of Funds

There are no Federal funds available to conduct the cosponsored activities for

the Children's Campaign. It will be the unilateral responsibility of the cosponsor(s) to bear all costs.

Eligibility of Cosponsorship

To be eligible, an interested party must be: (1) A public or private nonprofit or for-profit organization or corporation and (2) an entity that, by virtue of its nature and purpose, has a legitimate interest in the target groups.

Expression of Interest

Each request for cosponsorship should be in writing and contain information pertinent to the cosponsorship opportunity.

Evaluation Criteria

The cosponsors will be selected by the Children's Campaign management staff, CMHS, based on the following evaluation criteria: (1) The qualifications and capability of the interested party to develop and produce materials for dissemination of the Children's Campaign messages to the target population, and (2) the ability of the interested party to arrange for funding for development and dissemination of Children's Campaign information materials or messages.

Neither this notice nor actions pursuant thereto, creates a proprietary right or right of any kind in any natural or artificial person requesting cosponsorship. CMHS has the unilateral right to refuse to enter into a cosponsorship arrangement with any entity; exercise of this right is solely within the discretion of CMHS.

Other Information

Prior to the selection of the cosponsors, the Children's Campaign staff will meet separately with interested parties who best meet the evaluation criteria. In situations where the Food and Drug Administration (FDA) regulates the labeling of products manufactured by cosponsors, the inclusion of the Children's Campaign logo on such products will be subject to FDA review and may require agency authorization, depending on how and the context in which the logo is to be used. Moreover, other Federal agencies may be involved in the cosponsorship process. Furthermore, as a general rule, restrictions will apply to the use of the Children's Campaign logo or other indicia, to avoid suggestions that DHHS, or any other department or agency of the Federal Government, endorses any of the products involved in the Children's Campaign. Once details of the program have been mutually agreed upon, cosponsors will be required to enter into a cosponsorship agreement with the

CMHS setting forth the rights and responsibilities of the cosponsor and CMHS, especially the right of CMHS to approve the Children's Campaign messages and use of the Campaign logo.

Dated: February 29, 1996.

Richard Kopanda,

Acting Executive Officer, SAMHSA.

[FR Doc. 96-5119 Filed 3-4-96; 8:45 am]

BILLING CODE 4162-20-P

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an

on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300
 Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/205-263-5745
 American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900
 Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866
 Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787
 Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)
 Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444/800-877-7016
 Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5810
 Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310-215-6020
 Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800-445-6917
 CompuChem Laboratories, Inc., 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263/800-833-3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
 CORNING Clinical Laboratories, 4771 Regent Blvd., Irving, TX 75063, 800-526-0947 (formerly: Damon Clinical Laboratories, Damon/MetPath)
 CORNING Clinical Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 800-284-7515 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories)
 CORNING Clinical Laboratories, 24451 Telegraph Rd., Southfield, MI 48034, 800-444-0106 ext. 650 (formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath)
 CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 708-

595-3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)
 CORNING Clinical Laboratories, South Central Division, 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293 (formerly: Metropolitan Reference Laboratories, Inc.)
 CORNING Clinical Laboratory, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)
 CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science)
 CORNING Nichols Institute, 7470-A Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728/619-686-3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT))
 Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-836-3093
 Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, Great Lakes, IL 60088-5223, 708-688-2045/708-688-4171
 Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 813-936-5446/800-735-5416
 Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468,
 DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800-898-0180/206-386-2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)
 DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310
 ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609
 General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267
 Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800-725-3784/915-563-3300 (formerly: Harrison & Associates Forensic Laboratories)
 Holmes Regional Medical Center Toxicology Laboratory, 5200 Babcock St., N.E., Suite 107, Palm Bay, FL 32905, 407-726-9920
 Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513-569-2051
 LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913-888-3927 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.),
 Laboratory Corporation of America, 13900 Park Center Rd., Herndon, VA 22071, 703-742-3100 (Formerly: National Health Laboratories Incorporated)
 Laboratory Corporation of America, 21903 68th Ave. South, Kent, WA 98032, 206-395-4000 (Formerly: Regional Toxicology Services)
 Laboratory Corporation of America Holdings, 1120 Stateline Rd., Southaven, MS 38671, 601-342-1286 (Formerly: Roche Biomedical Laboratories, Inc.)
 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800-437-